PixarBio unveils Non-Opiate Pain Treatments Featured on Wall-Street.com

PixarBio is using patent pending formulations of FDA approved biomaterials and FDA approved non-opiate drugs to target key neurological areas to treat pain.

PixarBio is a company which specializes in the research and development of new technologies that are primarily aimed towards the treatment of pain. Established by Frank Reynods, inventor of NeuroScaffold™, the first treatment to restore function in humans after a traumatic spinal cord injury and winner of many awards such as life-time achievement award for curing paralysis from the National Spinal Injury Association, PixarBio is an industry-leader when it comes to non-opiate and non-addicting treatments for pain.

 

PixarBio is using patent pending formulations of FDA approved biomaterials and FDA approved non-opiate drugs to target key neurological areas to treat pain. Thanks to their team’s expertise on over 60 products approved by the FDA to start human studies, we have unmatched experience in the drug delivery system space and a track record of successfully developing FDA approved products.

 

One of the most advanced products ever developed by PixarBio is NeuroRelease which is a morphine-strength drug that is non-opiate and non-addicting especially targeted to become a post-surgical pain drug.

Another great product developed by this company is NeuroScaffolds. It is a drug which targets neuro protection and regeneration of the spinal cord following an injury.

 

All in all, PixarBio is without a doubt a leader in its own field whose products are aimed towards providing successful pain treatments.

About Wall-Street.com LLC

Wall-Street.com is a premier source for financial news worldwide. Stay up to date on the latest news. Wall-Street recognizes exceptional small cap and microcap companies and delivers a vast wealth of information in all areas of the financial industry.

Contact Information

Wall-Street.com LLC

40 WallStreet 28th Floor
New York
10005
United States
Phone : 2128513901
View website

Published in

Health

Published on

Aug 18, 2016

Latest News

Stay updated with the latest news and announcements.

Roofing Market Poised for Rapid Growth with 4.33% CAGR Through 2032

Roofing Market Poised for Rapid Growth with 4.33% CAGR Through 2032

The roofing market CAGR is a vibrant, quickly expanding business that is essential to the building industry.

Roofing   Apr 29, 2025